Pfizer Inc.
COMBINATION OF A CYCLIN DEPENDENT KINASE INHIBITOR AND A BET- BROMODOMAIN INHIBITOR

Abstract:

This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor that inhibits CDK4 and/or CDK6, and a bromodomain and extra-terminal domain (BET) family inhibitor, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.